BioCanada

Found 29,522 articles

• Braxia Scientific Provides Corporate Update and Reports Fiscal Fourth Quarter and Full-Year 2021 Financial Results

  7/30/2021

  TORONTO, July 30, 2021 /PRNewswire/ - Braxia Scientific Corp., announced the filing of its fiscal fourth-quarter and year-end results for the three- and 12-month periods ending March 31, 2021.

• Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

  7/30/2021

  Genetic Screening Platform Technology and Data to Strengthen Entheon's Psychedelic-Assisted Protocols.

• Relay Engages Top Cybersecurity Marketing Agency Bluetext for Cybeats Product Line

  7/30/2021

  Bluetext has an enviable reputation of developing successful marketing strategies for technical products in the cybersecurity industry for large and small organizations.

• Miravo HealthcareTM Ireland Enters into Suvexx License and Supply Agreement with SK Chemicals Co., Ltd. for South Korea

  7/29/2021

   Nuvo Pharmaceuticals Inc. (TSX: NRI) (OTCQX: NRIFF) d/b/a Miravo Healthcare ("Miravo" or the "Company"), today announced that its wholly owned subsidiary, Nuvo Pharmaceuticals (Ireland) DAC trading as Miravo Healthcare ("Miravo Ireland"), has entered into an exclusive license and supply agreement (the "License Agreement") with SK Chemicals Co., Ltd. ("SK Chemicals").

• Kane Biotech Receives Decisions to Grant for Two European Patents Providing Broad Protection of coactiv+™ Technology for Wound Care, Skin Infections and Personal Care Formulations

  7/29/2021

  Kane Biotech Inc. announces that it has received two Decisions to Grant from the European Patent Office for patents covering its best-in-class coactiv+™ technology.

• Microbion Corporation Appoints Robert A. Gillam as Chairman of Microbion's Board of Directors

  7/29/2021

  Microbion Corporation of Bozeman, MT, announced that Mr. Robert A. Gillam, CFA, will be joining Microbion's Board of Directors as Chairman, replacing Mr. Karim Lalji in the Board Chairman role effective immediately.

• IMV to Participate in the BTIG Virtual Biotechnology Conference

  7/29/2021

  IMV Inc. announced that members of IMV’s executive management team will be participating at the BTIG Virtual Biotechnology Conference which will be held on August 9-10 and will be participating in a fireside chat hosted by BTIG’s research team.

• Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5

  7/29/2021

  Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced that it has received approval for the listing of its common shares on the NYSE American LLC stock exchange.

• Baylis Medical Announces First Clinical Use of the VersaCross® Large Access Solution to Deliver Large Bore Therapy Solutions

  7/29/2021

  Baylis Medical announced the first clinical use of the VersaCross® Large Access Solution.

• Reminder: Acasti Pharma to Host Conference Call on August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics

  7/29/2021

  Acasti Pharma Inc. announces a reminder that it will host a business update conference call on Wednesday, August 4th at 1:00 PM ET to discuss the planned acquisition of Grace Therapeutics, Inc., a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases, as well as topics related to the annual and special meeting of shareholders.

• Statement from the Chief Public Health Officer of Canada on July 29, 2021

  7/29/2021

  As COVID-19 activity continues in Canada, we are continuing to track key epidemiological indicators to monitor trends and quickly detect emerging issues of concern, including to better understand the impact of circulating virus variants.

• Therma Bright Files Application to the OTCQB and DTC Clearing

  7/29/2021

  Therma Bright Inc. currently trades on the OTC Pink Sheets under the symbol THRBF.

• 

  Deep Genomics is Rewriting RNA for Powerful Therapeutics with $180M Series C

  7/28/2021

  "For the first time in history, medicine has become information." That's the groundbreaking connection AI-driven RNA therapeutics has given us, according to Deep Genomics Founder and CEO Brendan Frey. 

• Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01

  7/28/2021

  Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood glucose levels), today announced that it has dosed the first patients in its Phase 1b trial of ZT-01.

• Spectral Medical Inc. Provides Tigris Clinical Trial Update

  7/28/2021

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), today provided a clinical trial update on Tigris, a follow on study designed to build on knowledge gained from the earlier EUPHRATES trial, evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

• Levitee Labs Announces Completion of Acquisition of BlockMD Telemedicine Platform

  7/28/2021

  Levitee Labs Inc. (CSE: LVT) (the "Company" or "Levitee”), a biotechnology company with a diversified portfolio of healthcare and wellness assets, is pleased to announce that it has completed the acquisition of all the issued and outstanding shares of telemedicine company BlockMD Ltd. (“BlockMD”) as of July 27, 2021.

• Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3

  7/28/2021

   Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) applications for [225Ac]-FPI-1966 (FPI-1966) and imaging agent [111In]-FPI-1967 (FPI-1967).

• Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa® (Tucatinib) and Chemotherapy

  7/28/2021

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the first patient has been dosed with zanidatamab in combination with Tukysa® (tucatinib) and capecitabine in a new cohort of a Phase 1 trial for HER2-positive breast cancer patients with locally advanced (unresectable) and/or metastatic disease.

• VoxNeuro receives Health Canada Class II Medical Device designation

  7/28/2021

  VoxNeuro has received Health Canada Class II Medical Device designation for its proprietary Cognitive Health Assessment Management Platform™ (CHAMP). VoxNeuro will begin rolling out the software as a medical device across its Canadian Test Centers.

• XPhyto’s Acquisition Target, 3a-Diagnostics, Reports Breakthrough Identification of COVID-19 Biosensor Candidates

  7/28/2021

  XPhyto Therapeutics Corp. announces that its acquisition target, 3a-diagnostics GmbH has identified the first saliva activated "in-mouth" biosensor candidates for the detection of a COVID-19 infection.